Texas Department of State Health Services (DSHS) is applying for funds from Centers for Disease Control Funding Opportunity Announcement (FOA) PS21-2103 in order to maintain and improve the existing viral hepatitis program. Component 1 of the grant will be used to fund one existing program specialist III, one new program specialist III and one
epidemiologist I and its related activities. The HCV surveillance program will achieve the goals of the project through the following objectives:
1. Outcome 1: Develop, implement, and maintain plan to rapidly detect and respond to outbreaks of HCV.
Short-Term Outcomes: Established jurisdictional framework for outbreak detection and response and for earlier detection and response to HCV outbreaks.
Intermediate Outcomes: Improved response to HCV transmission clusters and outbreaks to reduce new cases of HCV.
2. Outcome 2: Systematically collect, analyze, interpret and disseminate HCV data to characterize trends in HCV transmission, detect active HCV transmission, and implement public health interventions.
Short-Term Outcomes: Increased public health reporting of acute and undetectable HCV RNA laboratory results and improved monitoring of burden of disease and trends in acute HCV infection.
Intermediate Outcomes: Improved monitoring of HCV continuum of cure (CoC).
3. Outcome 3: Systematically collect, analyze, interpret, and disseminate data to characterize trends and implement public health interventions for perinatal HCV.
Short-Term Outcomes: Improved monitoring of burden of disease and trends in perinatal HCV.
Intermediate Outcomes: Reduced number of new cases of perinatal HCV.
Component 2 of the grant will be used to fund the existing Viral Hepatitis Prevention Coordinator (VHPC) position and related activities. The VHPC will achieve the goals of the project through the following objectives:
1. Outcome 1: Begin viral hepatitis elimination planning through creation of a planning body and increasing engagement of key stakeholders throughout the state.
Short-Term Outcomes: Increased state engagement with key stakeholders in viral hepatitis elimination planning, increased commercial and hospital-based laboratories conducting HCV RNA reflex testing, and increased HCV and/or HBV testing in
health care systems.
Intermediate Outcomes: Increased health care providers trained in prescribing hepatitis C and hepatitis B treatment and increased access to HCV treatment.
2. Outcome 2: Increase access to HCV and HBV testing, treatment and prevention services and referral to care by expanding current partner organization services and identifying new partner organizations.
Short-Term Outcomes: Increased access to HCV RNA reflex testing among persons receiving services in high-impact settings, Increased awareness of infection status among people diagnosed with chronic hepatitis C and hepatitis B
Intermediate Outcomes: Increased cure of hepatitis C.
3. Outcome 3: Improved access to services preventing viral hepatitis and other blood-borne infections among PWID by increasing collaborations with Texas DSHS Immunization Unit and identifying partner organizations within the Texas Targeted Opioid Response Program.
Short Term Outcomes: Increased referral of PWID to SUD treatment and increased receipt of hepatitis A and B vaccination among